What is Roth Capital's Estimate for Accuray Q1 Earnings?

Key Points

• Roth Capital estimates that Accuray will report Q1 2027 earnings at ($0.02) per share, with a full-year consensus of $0.01 per share.
• Accuray's stock has decreased by 5.1%, reaching $1.39, and has a market capitalization of $156.01 million.
• Analyst ratings for Accuray have improved, with Wall Street Zen upgrading the stock to a "buy" rating and BTIG raising its target price from $4.00 to $5.00.

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Research analysts at Roth Capital issued their Q1 2027 earnings per share estimates for shares of Accuray in a report released on Wednesday, August 13th. Roth Capital analyst J. Wittes expects that the medical equipment provider will earn ($0.02) per share for the quarter. The consensus estimate for Accuray's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray's Q2 2027 earnings at ($0.01) EPS, Q3 2027 earnings at $0.01 EPS and Q4 2027 earnings at $0.03 EPS.

ARAY has been the topic of several other research reports. BTIG Research increased their price target on Accuray from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Wall Street Zen lowered Accuray from a "buy" rating to a "hold" rating in a report on Saturday. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $5.00.

Accuray Price Performance

Shares of Accuray stock remained flat at $1.51 on Friday. The company had a trading volume of 1,095,587 shares, compared to its average volume of 776,567. Accuray has a 52 week low of $1.1401 and a 52 week high of $2.95. The company has a debt-to-equity ratio of 3.35, a current ratio of 1.64 and a quick ratio of 0.92. The firm's 50 day moving average price is $1.35 and its two-hundred day moving average price is $1.61. The company has a market cap of $170.09 million, a P/E ratio of -75.50 and a beta of 1.24.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Accuray had a negative net margin of 0.35% and a negative return on equity of 5.79%. The business had revenue of $127.54 million for the quarter, compared to the consensus estimate of $123.78 million. Accuray has set its FY 2026 guidance at EPS.

Institutional Trading of Accuray

Several institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its stake in shares of Accuray by 604.2% in the second quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 30,182 shares during the last quarter. TENOR CAPITAL MANAGEMENT Co. L.P. purchased a new stake in shares of Accuray in the second quarter worth approximately $2,055,000. Globeflex Capital L P raised its stake in shares of Accuray by 35.1% in the second quarter. Globeflex Capital L P now owns 248,265 shares of the medical equipment provider's stock worth $340,000 after purchasing an additional 64,494 shares during the last quarter. Armistice Capital LLC raised its stake in shares of Accuray by 27.6% in the second quarter. Armistice Capital LLC now owns 3,236,000 shares of the medical equipment provider's stock worth $4,433,000 after purchasing an additional 700,000 shares during the last quarter. Finally, Sei Investments Co. raised its stake in shares of Accuray by 83.0% in the second quarter. Sei Investments Co. now owns 93,843 shares of the medical equipment provider's stock worth $129,000 after purchasing an additional 42,557 shares during the last quarter. 64.08% of the stock is owned by hedge funds and other institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.